All In Biotech

Free tool

FAERS Monitor: Aurlumyn

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217933 or its brand name (Aurlumyn, Iloprost). Reports on generic versions are filed under their own applications.

Reports

932

Serious

880

94% of reports

Hospitalization

381

Death reported

286

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective122
  • death77
  • off label use77
  • dyspnoea71
  • condition aggravated66
  • right ventricular failure64
  • pulmonary arterial hypertension59
  • hypotension52
  • pulmonary hypertension41
  • headache38
  • pneumonia38
  • maternal exposure during pregnancy37
  • sepsis36
  • cardiac failure35
  • premature baby35

Reports by year received

View as table
YearReports
20043
20058
20064
200715
200815
200921
201024
201115
201213
201317
201424
201530
201633
201743
201876
201992
202087
202180
202240
202369
202465
2025104
202654

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,227 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
right ventricular failureSignal64208.0164.012,863
pulmonary arterial hypertensionSignal5992.372.05,217
pulmonary hypertensionSignal4144.533.01,698
premature babySignal3526.319.0826
cardiac failureSignal359.87.1270
maternal exposure during pregnancySignal379.46.8269
sepsisSignal367.35.3190
hypotensionSignal525.94.5206
condition aggravatedSignal664.93.9204
dyspnoeaSignal712.82.385
pneumoniaSignal382.61.938
drug ineffectiveSignal1222.11.873
deathSignal772.01.640
off label use772.01.638
headache381.41.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.